Dyax Corp. (DYAX) PT Raised to $30 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Dyax Corp. (DYAX) PT Raised to $25 at Leerink Partners
April 1, 2015 8:37 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and boosted his price target on Dyax Corp. (NASDAQ: DYAX) to $25.00 (from $16.00) after the company announced data from its Phase Ib study of DX-2930 in Hereditary Angioedema (HAE).
Schwartz commented, "The study, which... More
Dyax (DYAX) PT Raised to $35 at Wedbush
April 1, 2015 7:02 AM EDTWedbush analyst Heather Behanna reiterated a Outperform rating and boosted her price target on Dyax Corp. (NASDAQ: DYAX) to $35.00 (from $18.00).
Behanna commented, "Small numbers, but data suggest DX-2930 could represent the new gold standard for HAE prophylaxis. Dyax reported its Phase Ib data on... More
Dyax Corp. (DYAX) PT Lifted to $31 at Jefferies
April 1, 2015 6:54 AM EDTJefferies analyst Biren Amin reiterated a Buy rating and boosted his price target on Dyax Corp. (NASDAQ: DYAX) to $31.00 (from $18.00) saying DX-2930 has potential as next standard of care in HAE.
DYAX reported detailed data from the PIb trial evaluating DX-2930 in patients w/... More
Dyax Corp (DYAX) DX-2930 Looks Great, Says RBC
March 31, 2015 4:56 PM EDTRBC Capital analyst Michael J. Yee commented on Dyax Corp (NASDAQ: DYAX) following the release of positive DX-2930 data in HAE. In his view, data "looks great" and is above expectations.
Yee explained, "Dyax reported Phase IB data for DX-2930. Efficacy and... More
Dyax Corp (DYAX) Announces Positive Results from Phase 1b Trial of DX-2930 and Fast Track Designation
March 31, 2015 4:04 PM EDTDyax Corp. (NASDAQ: DYAX) today announced positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of their investigational product, DX-2930. Discovered by Dyax, DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema (HAE) attacks.
The ongoing Phase 1b study is a multi-center, randomized, double-blind, placebo-controlled, multiple-ascending dose study designed to assess the safety, tolerability and pharmacokinetics of... More
